Ivonib (Ivosidenib) 250mg Tablets — IDH1 Inhibitor Generic for AML | Laos | GLT

Generic Information: Ivonib (Ivosidenib) — TLPH Laos

Ivonib is the ivosidenib product of Tongmeng (Lao) Pharmaceutical and Food Co., Ltd. (TLPH), supplied as 60 film-coated tablets of 250 mg in a sealed hospital-grade bottle with matching outer carton. Ivosidenib is the active ingredient of the originator brand Tibsovo — the first approved inhibitor of mutated IDH1 — and Ivonib brings that same molecule to the Lao market with full local registration, including the manufacturer's Lao license printed on the pack for buyer verification.

TLPH manufactures from its Vientiane facility under the slogan "Make Life Better", and its portfolio spans oncology, antivirals, and specialty generics distributed across the ASEAN region and exported further afield.

What Is Ivonib (Ivosidenib)?

Each Ivonib bottle holds sixty 250 mg tablets — one month of the standard once-daily ivosidenib regimen. The tablets are film-coated for stability and ease of swallowing, and the pack inserts include the Lao market's required regulatory statements. As a generic of an originator targeted therapy, Ivonib exists to solve one problem: in most of the world, the IDH1-mutated patients who need this drug cannot access it at originator pricing. A registered Lao product changes that equation.

How Does Ivonib (Ivosidenib) Work?

Inside IDH1-mutated cancer cells, the defective enzyme floods the cell with 2-hydroxyglutarate (2-HG), a metabolite that silences the maturation program of blood-forming cells. Ivosidenib blocks the mutant enzyme directly; 2-HG production falls, the maturation program restarts, and malignant blasts differentiate and clear. This "differentiation therapy" logic is unique to IDH1-directed treatment — it does not overlap with chemotherapy, BCL-2 inhibitors, or hypomethylating agents, which is why ivosidenib still works after those therapies have failed, and why it combines logically with azacitidine in newly diagnosed frail patients.

Indications Covered by Ivonib

• Relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation verified by validated testing.
• Newly diagnosed IDH1-mutated AML in adults 75 years or older, or with comorbidities excluding intensive chemotherapy, in combination with azacitidine where clinically chosen.
• Previously treated IDH1-mutated cholangiocarcinoma at the oncologist's discretion, following the originator's established evidence.

Dosage of Ivonib 250 mg

The regimen is 250 mg (one tablet) orally once daily, swallowed whole — not split, crushed, or chewed — at a consistent time each day, with or without food but not with a high-fat meal. Treatment continues until progression or unacceptable toxicity. Mandatory monitoring includes baseline and serial ECGs for QTc prolongation, electrolytes, and regular blood counts; prescribers also counsel patients about differentiation syndrome (fever, weight gain, breathing difficulty) so that corticosteroid treatment can start immediately if it appears. Dose interruptions and reductions follow the standard ivosidenib guidance for interactions and toxicities.

Side Effects of Ivonib (Ivosidenib)

Adverse reactions reflect the molecule, not the manufacturer: commonly fatigue, decreased white cells (neutropenia, leukopenia), diarrhea, edema, nausea, vomiting, mouth ulcers, abdominal pain, and QTc prolongation on electrocardiogram. The label-level serious risks — differentiation syndrome and significant QT prolongation — are monitorable and treatable when anticipated. Patients should report fever or breathlessness without delay and review all concurrent medicines with their physician, since several common drugs raise ivosidenib exposure.

Storage and Safety of Ivonib

Store the bottle tightly closed below 30°C, protected from moisture and light — ordinary ambient storage, no refrigeration. Keep out of children's reach. Note the carton's advisory that this is a prescription medicine dispensed only under professional supervision, and return unused tablets to a pharmacy for disposal.

Why Choose Ivonib from TLPH?

TLPH is an established, regulation-registered Lao manufacturer whose products are designed for export from day one — Lao licensing, English-language packs, and batch documentation that international buyers can verify. Ivonib gives IDH1-mutated AML patients the first-in-class mechanism at a small fraction of the originator's Western price, in the same 250 mg strength and once-daily routine. GIVE LIFE TIME LIMITED (GLT) works directly with TLPH supply channels and confirms registration, batch, and packaging integrity before every dispatch.

How to Order Ivonib (Ivosidenib)

To order Ivonib (ivosidenib 250 mg, 60 film-coated tablets), contact GIVE LIFE TIME LIMITED (GLT). We handle hospital procurement, licensed wholesaler supply, physician-guided purchases, and individual patient orders. Message us on WhatsApp at +86 15234153837 or email [email protected] for current availability and shipping details.

FAQ: Ivonib (Ivosidenib) Generic

Q: Who makes Ivonib?
A: Tongmeng (Lao) Pharmaceutical and Food Co., Ltd. — TLPH — at its Vientiane facility, under Lao regulatory registration.

Q: What is the pack size?
A: 60 film-coated 250 mg tablets per bottle, roughly one month of once-daily therapy.

Q: Is Ivonib the same as Tibsovo?
A: It contains the same active ingredient — ivosidenib 250 mg — produced as a registered Lao generic.

Q: What must be monitored during therapy?
A: ECGs for QTc, blood counts, electrolytes, and early signs of differentiation syndrome such as fever or breathlessness.

Q: How do I order Ivonib?
A: Contact GLT on WhatsApp +86 15234153837 or email [email protected] to confirm availability and delivery.